Press Release Details
Principia Biopharma Appoints Shawn Tomasello to Its Board of Directors
“We are very excited to have Shawn join our Board as she brings an extensive track record in developing and commercializing pharmaceutical products,” said
With more than 30 years of experience in the pharmaceutical and biotech industries, Ms. Tomasello has substantial commercial and strategic experience. From 2015 to 2018, Ms. Tomasello was chief commercial officer at leading immuno-oncology cell therapy company Kite Pharma, which was acquired by
Ms. Tomasello previously was president of the
Principia is a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Principia’s proprietary Tailored Covalency® platform enables the company to design and develop reversible and irreversible covalent, small molecule inhibitors with potencies and selectivities that have the potential to rival those of injectable biologics yet maintain the convenience of a pill. PRN1008, a reversible covalent BTK inhibitor, is being evaluated in a Phase 3 clinical trial in patients with pemphigus, an orphan autoimmune disease, and in a Phase 2 clinical trial in patients with immune thrombocytopenia, a rare hematological disease. PRN2246/
This press release contains forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Principia’s expectations regarding the Principia pipeline of product candidates and results from its current clinical trials. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Principia’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Principia’s business in general, see the risk factors set forth in Principia’s reports filed with the
Source: Principia Biopharma Inc.